Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wehrli

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its StromaMarc Wehrli, Samantha Guinn, Filippo Birocchi, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its StromaMarc Wehrli, Samantha Guinn, Filippo Birocchi, et al.
Pageof 3